Acurx Pharmaceuticals, Inc.2024财年第三财季实现净利润-2.82百万美元，同比增加9.32%

市场透视11-23

11月23日，Acurx Pharmaceuticals, Inc.（ACXP.US）公布财报，公告显示公司2024财年第三财季净利润为-2.82百万美元，同比增加9.32%；其中营业收入为0.00美元，每股基本收益为-0.17美元。从资产负债表来看，Acurx Pharmaceuticals, Inc.（ACXP.US）总负债3.32百万美元，其中短期债务0.00美元，资产负债比为1.81，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485989612?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485989612","market":"us","top_or_hot":-1,"title":"Acurx Pharmaceuticals, Inc.2024财年第三财季实现净利润-2.82百万美元，同比增加9.32%","media":"市场透视","content":"<div>\n<p>11月23日，Acurx Pharmaceuticals, Inc.（ACXP.US）公布财报，公告显示公司2024财年第三财季净利润为-2.82百万美元，同比增加9.32%；其中营业收入为0.00美元，每股基本收益为-0.17美元。从资产负债表来看，Acurx Pharmaceuticals, Inc.（ACXP.US）总负债3.32百万美元，其中短期债务0.00美元，资产负债比为1.81，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000022a24e4805&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acurx Pharmaceuticals, Inc.2024财年第三财季实现净利润-2.82百万美元，同比增加9.32%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcurx Pharmaceuticals, Inc.2024财年第三财季实现净利润-2.82百万美元，同比增加9.32%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000022a24e4805&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Acurx Pharmaceuticals, Inc.（ACXP.US）公布财报，公告显示公司2024财年第三财季净利润为-2.82百万美元，同比增加9.32%；其中营业收入为0.00美元，每股基本收益为-0.17美元。从资产负债表来看，Acurx Pharmaceuticals, Inc.（ACXP.US）总负债3.32百万美元，其中短期债务0.00美元，资产负债比为1.81，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000022a24e4805&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACXP","symbol_name":"Acurx Pharmaceuticals, LLC*","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000022a24e4805&s=b","article_id":"2485989612","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000022a24e4805&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485989612","pubTimestamp":1732291211,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Acurx Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-2.82百万美元，同比增加9.32%；其中营业收入为0.00美元，每股基本收益为-0.17美元。从资产负债表来看，Acurx Pharmaceuticals, Inc.总负债3.32百万美元，其中短期债务0.00美元，资产负债比为1.81，流动比率为1.81。机构评级：截至2024年11月23日，当前有2家机构对Acurx Pharmaceuticals, Inc.目标价做出预测，其中目标均价为11.00美元，其中最低目标价为10.00美元，最高目标价为12.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ACXP":"Acurx Pharmaceuticals, LLC*"},"translate_title":"Acurx Pharmaceuticals, Inc. achieved net profit of-US $2.82 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 9.32%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACXP":0.9},"content_text":"11月23日，Acurx Pharmaceuticals, Inc.（ACXP.US）公布财报，公告显示公司2024财年第三财季净利润为-2.82百万美元，同比增加9.32%；其中营业收入为0.00美元，每股基本收益为-0.17美元。从资产负债表来看，Acurx Pharmaceuticals, Inc.（ACXP.US）总负债3.32百万美元，其中短期债务0.00美元，资产负债比为1.81，流动比率为1.81。机构评级：截至2024年11月23日，当前有2家机构对Acurx Pharmaceuticals, Inc.目标价做出预测，其中目标均价为11.00美元，其中最低目标价为10.00美元，最高目标价为12.00美元。公司简介：Acurx Pharmaceuticals Inc是一家处于临床阶段的生物制药公司，正在开发一种新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品药品监督管理局列为优先病原体的细菌所引起的感染。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485989612"}